Evidence map›Paper›PMID 40548752›Full record

ArticleMicrobiology spectrum2025

Pentamidine inhibition of streptopain attenuates

Keya Trivedi, Christopher N LaRock

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Keya TrivediDepartment of Biology, Emory University, Atlanta, Georgia, USA.
Christopher N LaRockDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0003-3035-5331

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Proteolytic regulation of the Streptococcus pyogenes cell surfaceR01AI153071 · NIAID · EMORY UNIVERSITY · PI LAROCK, CHRISTOPHER N · 2021 to 2025
$1.9M
GSDMA roles in skin innate immune defenseR01AI180089 · NIAID · EMORY UNIVERSITY · PI Christopher N LaRock · 2024 to 2026
$1.8M
Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious DiseaseNIAID NIH HHS R01 AI153071NIAID NIH HHS R01 AI180089NIGMS NIH HHS R01 GM129325NIH HHS AI153071, AI180089
6 · The paper itself

Abstract

The obligate human pathogen

Indexed as

Anti-Bacterial AgentsBacterial ProteinsExotoxinsPentamidineStreptococcus pyogenesCysteine EndopeptidasesHumansStreptococcal InfectionsVirulenceVirulence FactorsAnti-Bacterial AgentsBacterial ProteinsCysteine EndopeptidasesExotoxinsPentamidinestreptopainVirulence Factorsantibioticsanti-infectivedrug repurposingproteaseStreptococcus pyogenesvirulence factor

Identifiers

PMID40548752
PMCPMC12323618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.